Adamis Pharmaceuticals (ADMP) Prices $6.7M Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 4% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
February 21, 2020 9:15 AM ESTSAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis or the Company) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $6.7 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. Â The combined purchase price for one share of common stock and 0.75 warrants will be $0.58.
Under the terms of the purchase agreement, Adamis has agreed to sell 11,600,000 shares of its common stock. Â In a concurrent private placement,... More
